Which has higher earnings and valuation, BVS or SMTI?

Bioventus has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $576.30M 1.52 $22.73M $0.41 25.56 Sanara MedTech $103.12M 2.21 -$37.56M -$3.77 N/A

Does the media refer more to BVS or SMTI?

In the previous week, Bioventus had 1 more articles in the media than Sanara MedTech. MarketBeat recorded 2 mentions for Bioventus and 1 mentions for Sanara MedTech. Bioventus' average media sentiment score of 0.33 beat Sanara MedTech's score of 0.00 indicating that Bioventus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sanara MedTech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, SIBN or SMTI?

SiBone has higher revenue and earnings than Sanara MedTech. SiBone is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 3.78 -$18.90M -$0.39 N/A Sanara MedTech $103.12M 2.21 -$37.56M -$3.77 N/A

Is SIBN or SMTI more profitable?

SiBone has a net margin of -8.10% compared to Sanara MedTech's net margin of -31.23%. Sanara MedTech's return on equity of -3.19% beat SiBone's return on equity. Company Net Margins Return on Equity Return on Assets SiBone -8.10% -9.56% -7.06% Sanara MedTech -31.23% -3.19% -0.56%

Does the media refer more to SSII or SMTI?

In the previous week, SS Innovations International had 4 more articles in the media than Sanara MedTech. MarketBeat recorded 5 mentions for SS Innovations International and 1 mentions for Sanara MedTech. SS Innovations International's average media sentiment score of 0.72 beat Sanara MedTech's score of 0.00 indicating that SS Innovations International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SS Innovations International 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanara MedTech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, CBLL or SMTI?

Sanara MedTech has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CeriBell $95.07M 7.80 -$53.41M -$1.63 N/A Sanara MedTech $103.12M 2.21 -$37.56M -$3.77 N/A

Does the media refer more to CBLL or SMTI?

In the previous week, CeriBell had 6 more articles in the media than Sanara MedTech. MarketBeat recorded 7 mentions for CeriBell and 1 mentions for Sanara MedTech. CeriBell's average media sentiment score of 0.63 beat Sanara MedTech's score of 0.00 indicating that CeriBell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Sanara MedTech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SGP or SMTI?

In the previous week, Spyglass Pharma and Spyglass Pharma both had 1 articles in the media. Spyglass Pharma's average media sentiment score of 0.00 equaled Sanara MedTech'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyglass Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sanara MedTech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Sanara MedTech (SMTI) Competitors

$24.84 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$24.84 0.00 (-0.02%)

As of 07/2/2026 04:10 PM Eastern

Compare

SMTI vs. BVS, SIBN, SSII, CBLL, and SGP

Should you buy Sanara MedTech stock or one of its competitors? MarketBeat compares Sanara MedTech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sanara MedTech include Bioventus (BVS), SiBone (SIBN), SS Innovations International (SSII), CeriBell (CBLL), and Spyglass Pharma (SGP). These companies are all part of the "medical equipment" industry.

How does Sanara MedTech compare to Bioventus?

Bioventus (NASDAQ:BVS) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Bioventus has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$576.30M	1.52	$22.73M	$0.41	25.56
Sanara MedTech	$103.12M	2.21	-$37.56M	-$3.77	N/A

Bioventus presently has a consensus target price of $14.20, indicating a potential upside of 35.50%. Sanara MedTech has a consensus target price of $34.00, indicating a potential upside of 36.88%. Given Sanara MedTech's higher probable upside, analysts plainly believe Sanara MedTech is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Bioventus has a net margin of 4.94% compared to Sanara MedTech's net margin of -31.23%. Bioventus' return on equity of 29.97% beat Sanara MedTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	4.94%	29.97%	9.52%
Sanara MedTech	-31.23%	-3.19%	-0.56%

In the previous week, Bioventus had 1 more articles in the media than Sanara MedTech. MarketBeat recorded 2 mentions for Bioventus and 1 mentions for Sanara MedTech. Bioventus' average media sentiment score of 0.33 beat Sanara MedTech's score of 0.00 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sanara MedTech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

62.9% of Bioventus shares are owned by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are owned by institutional investors. 33.0% of Bioventus shares are owned by insiders. Comparatively, 42.0% of Sanara MedTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Bioventus has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

Summary

Bioventus beats Sanara MedTech on 12 of the 16 factors compared between the two stocks.

How does Sanara MedTech compare to SiBone?

SiBone (NASDAQ:SIBN) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

In the previous week, Sanara MedTech had 1 more articles in the media than SiBone. MarketBeat recorded 1 mentions for Sanara MedTech and 0 mentions for SiBone. SiBone's average media sentiment score of 0.00 equaled Sanara MedTech'saverage media sentiment score.

Company	Overall Sentiment
SiBone	Neutral
Sanara MedTech	Neutral

SiBone currently has a consensus price target of $23.00, indicating a potential upside of 34.42%. Sanara MedTech has a consensus price target of $34.00, indicating a potential upside of 36.88%. Given Sanara MedTech's higher probable upside, analysts clearly believe Sanara MedTech is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

98.1% of SiBone shares are owned by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are owned by institutional investors. 4.0% of SiBone shares are owned by company insiders. Comparatively, 42.0% of Sanara MedTech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

SiBone has higher revenue and earnings than Sanara MedTech. SiBone is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	3.78	-$18.90M	-$0.39	N/A
Sanara MedTech	$103.12M	2.21	-$37.56M	-$3.77	N/A

SiBone has a net margin of -8.10% compared to Sanara MedTech's net margin of -31.23%. Sanara MedTech's return on equity of -3.19% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
Sanara MedTech	-31.23%	-3.19%	-0.56%

SiBone has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

Summary

SiBone and Sanara MedTech tied by winning 8 of the 16 factors compared between the two stocks.

How does Sanara MedTech compare to SS Innovations International?

SS Innovations International (NASDAQ:SSII) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

8.1% of Sanara MedTech shares are owned by institutional investors. 42.0% of Sanara MedTech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

SS Innovations International has higher earnings, but lower revenue than Sanara MedTech. SS Innovations International is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SS Innovations International	$42.49M	17.80	-$12.13M	-$0.05	N/A
Sanara MedTech	$103.12M	2.21	-$37.56M	-$3.77	N/A

SS Innovations International presently has a consensus price target of $7.00, suggesting a potential upside of 85.19%. Sanara MedTech has a consensus price target of $34.00, suggesting a potential upside of 36.88%. Given SS Innovations International's higher possible upside, equities analysts plainly believe SS Innovations International is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

SS Innovations International has a net margin of -20.69% compared to Sanara MedTech's net margin of -31.23%. Sanara MedTech's return on equity of -3.19% beat SS Innovations International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SS Innovations International	-20.69%	-23.00%	-13.18%
Sanara MedTech	-31.23%	-3.19%	-0.56%

In the previous week, SS Innovations International had 4 more articles in the media than Sanara MedTech. MarketBeat recorded 5 mentions for SS Innovations International and 1 mentions for Sanara MedTech. SS Innovations International's average media sentiment score of 0.72 beat Sanara MedTech's score of 0.00 indicating that SS Innovations International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SS Innovations International	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanara MedTech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SS Innovations International has a beta of -1.96, suggesting that its share price is 296% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market.

Summary

Sanara MedTech beats SS Innovations International on 10 of the 17 factors compared between the two stocks.

How does Sanara MedTech compare to CeriBell?

CeriBell (NASDAQ:CBLL) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

CeriBell has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market.

8.1% of Sanara MedTech shares are held by institutional investors. 20.1% of CeriBell shares are held by insiders. Comparatively, 42.0% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Sanara MedTech has a net margin of -31.23% compared to CeriBell's net margin of -63.51%. Sanara MedTech's return on equity of -3.19% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
Sanara MedTech	-31.23%	-3.19%	-0.56%

CeriBell currently has a consensus target price of $22.20, indicating a potential upside of 13.55%. Sanara MedTech has a consensus target price of $34.00, indicating a potential upside of 36.88%. Given Sanara MedTech's higher possible upside, analysts plainly believe Sanara MedTech is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, CeriBell had 6 more articles in the media than Sanara MedTech. MarketBeat recorded 7 mentions for CeriBell and 1 mentions for Sanara MedTech. CeriBell's average media sentiment score of 0.63 beat Sanara MedTech's score of 0.00 indicating that CeriBell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanara MedTech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sanara MedTech has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$95.07M	7.80	-$53.41M	-$1.63	N/A
Sanara MedTech	$103.12M	2.21	-$37.56M	-$3.77	N/A

Summary

Sanara MedTech beats CeriBell on 10 of the 16 factors compared between the two stocks.

How does Sanara MedTech compare to Spyglass Pharma?

Spyglass Pharma (NASDAQ:SGP) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

8.1% of Sanara MedTech shares are owned by institutional investors. 42.0% of Sanara MedTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Spyglass Pharma has higher earnings, but lower revenue than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	N/A	-$6.41	N/A
Sanara MedTech	$103.12M	2.21	-$37.56M	-$3.77	N/A

Spyglass Pharma currently has a consensus target price of $45.00, indicating a potential upside of 134.99%. Sanara MedTech has a consensus target price of $34.00, indicating a potential upside of 36.88%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Spyglass Pharma is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Spyglass Pharma has a net margin of 0.00% compared to Sanara MedTech's net margin of -31.23%. Spyglass Pharma's return on equity of 0.00% beat Sanara MedTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	N/A	N/A
Sanara MedTech	-31.23%	-3.19%	-0.56%

In the previous week, Spyglass Pharma and Spyglass Pharma both had 1 articles in the media. Spyglass Pharma's average media sentiment score of 0.00 equaled Sanara MedTech'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyglass Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sanara MedTech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Spyglass Pharma beats Sanara MedTech on 7 of the 12 factors compared between the two stocks.

Get Sanara MedTech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SMTI vs. The Competition

Export

Metric	Sanara MedTech	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$227.63M	$8.77B	$7.18B	$12.47B
Dividend Yield	N/A	2.45%	2.66%	6.50%
P/E Ratio	-6.59	16.55	28.02	24.70
Price / Sales	2.21	6.93	532.59	97.92
Price / Cash	41.78	18.11	49.26	57.09
Price / Book	37.07	3.53	10.96	6.46
Net Income	-$37.56M	$226.25M	$3.57B	$337.01M
7 Day Performance	4.02%	1.50%	2.12%	1.69%
1 Month Performance	10.70%	-0.23%	5.25%	3.81%
1 Year Performance	-16.85%	-0.49%	33.29%	23.90%

Sanara MedTech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SMTI Sanara MedTech	1.8154 of 5 stars	$24.84 flat	$34.00 +36.9%	-16.9%	$227.63M	$103.12M	N/A	60	News Coverage Positive News Analyst Upgrade
BVS Bioventus	4.1175 of 5 stars	$9.71 +4.5%	$14.20 +46.3%	N/A	$811.59M	$568.09M	23.70	1,200	News Coverage Analyst Forecast
SIBN SiBone	1.8128 of 5 stars	$16.57 +3.9%	$23.00 +38.8%	-7.3%	$733.55M	$200.93M	N/A	350	Positive News
SSII SS Innovations International	2.2609 of 5 stars	$3.62 +6.5%	$7.00 +93.4%	-29.2%	$724.48M	$48.47M	N/A	4	Gap Up
CBLL CeriBell	1.794 of 5 stars	$19.01 +3.4%	$22.20 +16.8%	+3.3%	$719.95M	$89.06M	N/A	N/A	News Coverage Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SMTI) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sanara MedTech (SMTI) Competitors

SMTI vs. BVS, SIBN, SSII, CBLL, and SGP

How does Sanara MedTech compare to Bioventus?

Summary

How does Sanara MedTech compare to SiBone?

Summary

How does Sanara MedTech compare to SS Innovations International?

Summary

How does Sanara MedTech compare to CeriBell?

Summary

How does Sanara MedTech compare to Spyglass Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMTI vs. The Competition

Sanara MedTech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sanara MedTech (SMTI) Competitors

SMTI vs. BVS, SIBN, SSII, CBLL, and SGP

How does Sanara MedTech compare to Bioventus?

Which has higher earnings and valuation, BVS or SMTI?

Do analysts recommend BVS or SMTI?

Is BVS or SMTI more profitable?

Does the media refer more to BVS or SMTI?

Do insiders & institutionals have more ownership in BVS or SMTI?

Which has more volatility and risk, BVS or SMTI?

Summary

How does Sanara MedTech compare to SiBone?

Does the media refer more to SIBN or SMTI?

Do analysts recommend SIBN or SMTI?

Do insiders and institutionals have more ownership in SIBN or SMTI?

Which has preferable valuation and earnings, SIBN or SMTI?

Is SIBN or SMTI more profitable?

Which has more risk & volatility, SIBN or SMTI?

Summary

How does Sanara MedTech compare to SS Innovations International?

Do insiders & institutionals have more ownership in SSII or SMTI?

Which has stronger earnings & valuation, SSII or SMTI?

Do analysts prefer SSII or SMTI?

Is SSII or SMTI more profitable?

Does the media refer more to SSII or SMTI?

Which has more volatility & risk, SSII or SMTI?

Summary

How does Sanara MedTech compare to CeriBell?

Which has more volatility and risk, CBLL or SMTI?

Do insiders and institutionals believe in CBLL or SMTI?

Is CBLL or SMTI more profitable?

Do analysts prefer CBLL or SMTI?

Does the media refer more to CBLL or SMTI?

Which has higher earnings & valuation, CBLL or SMTI?

Summary

How does Sanara MedTech compare to Spyglass Pharma?

Do insiders & institutionals have more ownership in SGP or SMTI?

Which has preferable valuation & earnings, SGP or SMTI?

Do analysts recommend SGP or SMTI?

Is SGP or SMTI more profitable?

Does the media refer more to SGP or SMTI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SMTI vs. The Competition

Sanara MedTech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools